A prospective trial evaluating topographical distribution of tau pathology and its effect on functional and structural changes in healthy controls and patients with Alzheimer disease and mild cognitive impairment (MCI) by using 18F-AV-1451 PET.

Trial Profile

A prospective trial evaluating topographical distribution of tau pathology and its effect on functional and structural changes in healthy controls and patients with Alzheimer disease and mild cognitive impairment (MCI) by using 18F-AV-1451 PET.

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Jul 2016

At a glance

  • Drugs Flortaucipir F 18 (Primary) ; Florbenazine F18
  • Indications Alzheimer's disease; Mild cognitive impairment
  • Focus Diagnostic use
  • Most Recent Events

    • 14 Jul 2016 New trial record
    • 29 Jun 2016 Results published in the Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top